A Randomized, Blinded, Placebo-controlled, Dose Escalation Study to Evaluate the Safety, Tolerability and Pharmacokinetics of HQK-1001 in Subjects With Sickle Cell Disease
Latest Information Update: 21 Mar 2014
At a glance
- Drugs HQK 1001 (Primary)
- Indications Sickle cell anaemia
- Focus Adverse reactions
- Sponsors HemaQuest Pharmaceuticals
- 21 Mar 2014 New trial record